{"version":"1.0","provider_name":"Frezza Partners","provider_url":"https:\/\/frezzapartners.com\/en\/","author_name":"Frezza Partners","author_url":"https:\/\/frezzapartners.com\/en\/author\/fr3zz4partn3rs\/","title":"MSD acquisisce OncoImmune per rafforzare la pipeline anti-Covid - Frezza Partners","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"l1Vx5gSCtg\"><a href=\"https:\/\/frezzapartners.com\/en\/msd-acquisisce-oncoimmune\/\">MSD acquisisce OncoImmune per rafforzare la pipeline anti-Covid<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/frezzapartners.com\/en\/msd-acquisisce-oncoimmune\/embed\/#?secret=l1Vx5gSCtg\" width=\"600\" height=\"338\" title=\"&#8220;MSD acquisisce OncoImmune per rafforzare la pipeline anti-Covid&#8221; &#8212; Frezza Partners\" data-secret=\"l1Vx5gSCtg\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/frezzapartners.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/11\/girl-5760039_1920.jpg","thumbnail_width":1920,"thumbnail_height":1280,"description":"photo by Marcos Cola &nbsp; MSD e OncoImmune, societ\u00e0 clinical-stage biofarmaceutica privata, hanno annunciato di aver stipulato un accordo definitivo ai sensi del quale MSD, tramite una controllata, acquisir\u00e0 tutte le azioni in circolazione di OncoImmune per un pagamento anticipato di $ 425 milioni in contanti. Inoltre, gli azionisti di OncoImmune potranno ricevere pagamenti basati sulle vendite e pagamenti subordinati al raggiungimento di determinati traguardi normativi. OncoImmune ha recentemente annunciato risultati top-line positivi da un&#8217;analisi di efficacia ad interim di..."}